Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14167270 | 1.00 | DPP4 (0.41) | DPP4CITROCK2AAK1HIPK4 | |
| SCHEMBL24814569 | 0.80 | NOS2 (0.30) | — | |
| SCHEMBL14347046 | 0.78 | DPP7 (0.39) | DPP4CITROCK2AAK1HIPK4 | |
| SCHEMBL25530472 | 0.78 | DPP4 (0.36) | DPP4CITROCK2AAK1HIPK4 | |
| SCHEMBL24815290 | 0.77 | DPP7 (0.42) | DPP4MMP1MMP3MMP2 | |
| SCHEMBL23836662 | 0.75 | ALDH1A1 (0.47) | DPP4CITROCK2 | |
| SCHEMBL24996110 | 0.75 | CYP2D6 (0.43) | DPP4CITROCK2AAK1CACNA1B | |
| SCHEMBL18774906 | 0.75 | CASR (0.38) | DPP4CITROCK2AAK1HIPK4 | |
| SCHEMBL18712170 | 0.75 | ALDH1A1 (0.47) | DPP4CITROCK2 | |
| SCHEMBL18774908 | 0.75 | DPP4 (0.37) | DPP4CITROCK2AAK1HIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718266-B9 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-3072886-A1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-2718266-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | claimed |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2016-05-19 | — | — | US | claimed |
| US-9321727-B2 | Pyridine derivatives as agonists of the CB2 receptor | HOFFMANN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-9290451-B2 | — | — | 2016-03-22 | — | — | US | claimed |
| EP-2718266-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168350-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | claimed |
| EP-3072886-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| EP-2718266-B9 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-3072886-A1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2718266-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2016-05-19 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157751-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885CIT 3177/4885ROCK2 4507/4885 |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885CIT 3177/4885ROCK2 4507/4885 |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | DPP4 2226/4885CIT 3837/4885ROCK2 3369/4885 |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | DPP4 2226/4885CIT 3837/4885ROCK2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.